<code id='BBF6CC1D45'></code><style id='BBF6CC1D45'></style>
    • <acronym id='BBF6CC1D45'></acronym>
      <center id='BBF6CC1D45'><center id='BBF6CC1D45'><tfoot id='BBF6CC1D45'></tfoot></center><abbr id='BBF6CC1D45'><dir id='BBF6CC1D45'><tfoot id='BBF6CC1D45'></tfoot><noframes id='BBF6CC1D45'>

    • <optgroup id='BBF6CC1D45'><strike id='BBF6CC1D45'><sup id='BBF6CC1D45'></sup></strike><code id='BBF6CC1D45'></code></optgroup>
        1. <b id='BBF6CC1D45'><label id='BBF6CC1D45'><select id='BBF6CC1D45'><dt id='BBF6CC1D45'><span id='BBF6CC1D45'></span></dt></select></label></b><u id='BBF6CC1D45'></u>
          <i id='BBF6CC1D45'><strike id='BBF6CC1D45'><tt id='BBF6CC1D45'><pre id='BBF6CC1D45'></pre></tt></strike></i>

          
          WSS
          A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024
          Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

          Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

          Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

          advertisement

          The firm also said that it would be raising $500 million through a stock sale. 

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment